In addition, in relation with the administration of bioactive compounds, pursuing the development of activity at neural tissues and in the frame of deficits or overexpression of neurotrophins, responsible for neurodegenerative diseases and psychiatric disorders, to date, the research has demonstrated a delivery system competent to control of neurotrophin dosage in the brain. The gene discussed is BDNF; the disease is psychiatric disorder.